Background The newly described SARS-CoV-2 lineage C.37 was recently classified as a
variant of interest by the WHO (Lambda variant) based on its high circulation rates in South …

CoronaVac is an inactivated SARS-CoV-2 vaccine approved by the World Health Organization
(WHO). Previous studies reported increased levels of neutralizing antibodies and specific …

SARS-CoV-2 variant Lambda was dominant in several South American countries, including
Chile. To ascertain the efficacy of local vaccination efforts, we used pseudotyped viruses to …

Multiple vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
have been evaluated in clinical trials. However, trials addressing the immune response in the …

During retroviral replication, the full-length RNA serves both as mRNA and genomic RNA.
However, the mechanisms by which the HIV-1 Gag protein selects the two RNA molecules that …

Background Chile was severely affected by COVID19 outbreaks but was also one of the first
countries to start a nationwide program to vaccinate against the disease. Furthermore, Chile …

CoronaVac vaccine from Sinovac Life Science is currently being used in several countries.
In Chile, the effectiveness of preventing hospitalization is higher than 80% with a vaccination …

Background By June 30, 2022, 92·6% of the Chilean population older than 18 years had
received a full primary SARS-CoV-2 vaccine series, mostly with CoronaVac (Sinovac Biotech), …

Background: The development of vaccines to control the coronavirus disease 2019 (COVID-19)
pandemic progression is a worldwide priority. CoronaVac is an inactivated severe acute …

… Acevedo, # 1, 2 Aracelly Gaete-Argel, # 1 Luis Alonso-Palomares, 1 Marco Montes de
Oca, 3 Andrés Bustamante, 1 Aldo Gaggero, 4 Fabio Paredes, 5 Claudia P. Cortes, 2, 6, 7 …